134 related articles for article (PubMed ID: 3034039)
1. Effect of ramipril on 24-hour variability of blood pressure and heart rate in essential hypertension.
Tochikubo O; Asahina S; Kaneko Y
Am J Cardiol; 1987 Apr; 59(10):83D-85D. PubMed ID: 3034039
[TBL] [Abstract][Full Text] [Related]
2. Effect of ramipril, a new angiotensin converting enzyme inhibitor, on diurnal variations of blood pressure in essential hypertension.
Kaneko Y; Omae T; Yoshinaga K; Iimura O; Inagaki Y; Ishii M; Saruta T; Yamada K; Kumahara Y; Ito K
Am J Cardiol; 1987 Apr; 59(10):86D-91D. PubMed ID: 3034040
[TBL] [Abstract][Full Text] [Related]
3. Studies on the antihypertensive effect of single doses of the angiotensin converting enzyme inhibitor ramipril (HOE 498) in man.
Böhm RO; van Baak MA; Rahn KH
Eur J Clin Pharmacol; 1986; 30(5):541-7. PubMed ID: 3019702
[TBL] [Abstract][Full Text] [Related]
4. Blood pressure response of nephrectomized subjects and patients with essential hypertension to ramipril: indirect evidence that inhibition of tissue angiotensin converting enzyme is important.
Wenting GJ; Blankestijn PJ; Poldermans D; van Geelen J; Derkx FH; Man in't Veld AJ; Schalekamp MA
Am J Cardiol; 1987 Apr; 59(10):92D-97D. PubMed ID: 3034041
[TBL] [Abstract][Full Text] [Related]
5. Combined treatment of severe essential hypertension with the new angiotensin converting enzyme inhibitor ramipril.
Predel HG; Düsing R; Bäcker A; Kipnowski J; Kramer HJ
Am J Cardiol; 1987 Apr; 59(10):143D-148D. PubMed ID: 3034023
[TBL] [Abstract][Full Text] [Related]
6. Effects of the new angiotensin-converting enzyme inhibitor, ramipril, in patients with essential hypertension.
Stumpe KO; Overlack A; Kolloch R; Schatz J; Witte PU; Pahnke K
Klin Wochenschr; 1986 Jun; 64(12):558-62. PubMed ID: 3016405
[TBL] [Abstract][Full Text] [Related]
7. Short- and long-term effects of ramipril in hypertension.
de Leeuw PW; Birkenhäger WH
Am J Cardiol; 1987 Apr; 59(10):79D-82D. PubMed ID: 3034038
[TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacology of ramipril.
Ball SG; Robertson JI
Am J Cardiol; 1987 Apr; 59(10):23D-27D. PubMed ID: 3034028
[TBL] [Abstract][Full Text] [Related]
9. Humoral and blood pressure effects of the angiotensin converting enzyme inhibitor ramipril in essential hypertension.
Lenz T; Distler A; Haller H; Meyer-Sabellek W; Wilp C; Tansey MJ; Eckert HG; Metzger H; Irmisch R; Philipp T
Arzneimittelforschung; 1986 Nov; 36(11):1693-6. PubMed ID: 3028438
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, tolerance and hormonal effects of a new oral angiotensin converting enzyme inhibitor, ramipril (HOE 498), in mild to moderate primary hypertension.
Karlberg BE; Lindström T; Rosenqvist U; Ohman KP
Am J Cardiol; 1987 Apr; 59(10):104D-109D. PubMed ID: 3034016
[TBL] [Abstract][Full Text] [Related]
11. Significance of kallikrein-kinin and renin-angiotensin systems in the hypotensive mechanism of angiotensin-I converting enzyme inhibitors in essential hypertensives.
Iimura O; Shimamoto K
Adv Exp Med Biol; 1989; 247A():39-48. PubMed ID: 2532450
[TBL] [Abstract][Full Text] [Related]
12. First dose response and 24-hour antihypertensive efficacy of the new once-daily angiotensin converting enzyme inhibitor, ramipril.
Heber ME; Brigden GS; Caruana MP; Lahiri A; Raftery EB
Am J Cardiol; 1988 Aug; 62(4):239-45. PubMed ID: 2969671
[TBL] [Abstract][Full Text] [Related]
13. An open multicenter study to assess the long-term efficacy, tolerance, and safety of the oral angiotensin converting enzyme inhibitor ramipril in patients with mild to moderate essential hypertension.
Bauer B; Lorenz H; Zahlten R
J Cardiovasc Pharmacol; 1989; 13 Suppl 3():S70-4. PubMed ID: 2474109
[TBL] [Abstract][Full Text] [Related]
14. Comparative double-blind study of ramipril and captopril in mild to moderate essential hypertension.
Witte PU; Walter U
Am J Cardiol; 1987 Apr; 59(10):115D-120D. PubMed ID: 3034018
[TBL] [Abstract][Full Text] [Related]
15. Metabolic effects of ramipril treatment in hypertensive subjects with non-insulin-dependent diabetes mellitus.
Janka HU; Nuber A; Mehnert H
Arzneimittelforschung; 1990 Apr; 40(4):432-5. PubMed ID: 2141472
[TBL] [Abstract][Full Text] [Related]
16. Ambulatory 24-h blood pressure monitoring in essential hypertensives treated with the angiotensin-converting enzyme inhibitor ramipril.
Spieker C; Zidek W; Vetter H; Rahn KH
J Int Med Res; 1991; 19(1):39-43. PubMed ID: 1826891
[TBL] [Abstract][Full Text] [Related]
17. Preliminary experiences with HOE 498, a novel long-acting converting enzyme inhibitor, in hypertensive patients.
de Leeuw PW; Lugtenburg PL; van Houten H; Looman JH; Birkenhäger WH
J Cardiovasc Pharmacol; 1985; 7(6):1161-5. PubMed ID: 2418304
[TBL] [Abstract][Full Text] [Related]
18. A double-blind study to compare the efficacy, tolerance and safety of two doses of the angiotensin converting enzyme inhibitor ramipril with placebo.
Villamil AS; Cairns V; Witte PU; Bertolasi CA
Am J Cardiol; 1987 Apr; 59(10):110D-114D. PubMed ID: 3034017
[TBL] [Abstract][Full Text] [Related]
19. The effect of ramipril on ambulatory blood pressure: a multicenter trial.
Burris JF
J Cardiovasc Pharmacol; 1991; 18 Suppl 2():S131-3. PubMed ID: 1725022
[TBL] [Abstract][Full Text] [Related]
20. Dose-response relationship of ramipril in patients with mild-to-moderate hypertension.
Schnaper HW
J Cardiovasc Pharmacol; 1991; 18 Suppl 2():S128-30. PubMed ID: 1725021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
